-
Product Insights
Carraig Gheal (Loch Awe)
Carraig Gheal (Loch Awe) is an Onshore Wind project located in Scotland, United Kingdom. The project is owned and developed by GreenPower Developments Ltd. The project came online in 2013. Empower your strategies with our Carraig Gheal (Loch Awe) report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the...
-
Sector Analysis
NewIT Management Market Size, Trends, Drivers and Challenges, Vendor Landscape, Opportunities and Forecast to 2027
IT Management Market Overview The IT Management market size was pegged at more than $195 billion in 2022. The market is expected to grow at a CAGR of more than 7% during the forecast period (2022-2027). The speed at which businesses are completing their digital transformation initiatives is encouraging for the IT management sector since this sector is vital in helping businesses create scalable, reliable IT infrastructures that can support their digital endeavors. IT Management Market Outlook, 2022-2027 ($ Billions)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Refractory Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Relapsed Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Chronic Lymphocytic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Multiple Myeloma...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Diffuse Large...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Follicular Lymphoma Drug Details:...
-
Company Insights
NewElevance Health – Digital Transformation Strategies
Elevance Health Digital Transformation Strategies Overview Elevance Health is tapping the power of big data analytics to analyze data and generate insights, improve member engagement, and detect fraudulent claims. AI, big data, cloud, and automation are among the key technologies under focus for the company. The annual ICT spending of Elevance Health was estimated at $3.8 billion in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Elevance Health Inc...